NCT03606057View on ClinicalTrials.gov

A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)

PHASE1CompletedINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

July 13, 2018

Primary Completion Date

February 8, 2019

Study Completion Date

February 28, 2019

Conditions
Healthy
Interventions
DRUG

JNJ-64565111

Participants will receive JNJ-64565111, subcutaneously on days 2, 9, 16, and 23.

DRUG

Moxifloxacin

Participants will receive moxifloxacin capsule on days 1 or 27 in a nested crossover manner.

DRUG

JNJ-64565111-matching Placebo

Participants will receive JNJ-64565111-matching Placebo vehicle solution subcutaneously on days 2, 9, 16, and 23.

DRUG

Moxifloxacin-matching Placebo

Participants will receive moxifloxacin-matching placebo capsule on days 1 and 27 in treatment group 1 and on day 1 or 27 in treatment group 2.

Trial Locations (1)

85283

Celerion, Tempe

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT03606057 - A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin) | Biotech Hunter | Biotech Hunter